Loading...
ROCO
4174
Market cap123mUSD
Jul 09, Last price  
30.20TWD
1D
2.03%
1Q
-20.53%
Jan 2017
-89.40%
IPO
-90.16%
Name

OBI Pharma Inc

Chart & Performance

D1W1MN
ROCO:4174 chart
P/E
—
P/S
67.84
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-8.10%
Rev. gr., 5y
-16.10%
Revenues
59m
-6.55%
0000092,422,000376,00013,339,000872,000140,886,00018,772,0004,711,00041,549,00062,678,00058,575,000
Net income
-2.05b
L-11.13%
-127,587,000-255,275,000-438,584,000-667,007,000-941,337,000-1,110,128,000-1,379,436,000-1,222,242,000-1,439,590,000-1,489,897,000-1,717,890,000-1,899,324,000-1,046,475,000-2,310,026,000-2,052,822,999
CFO
-2.02b
L+10.18%
-508,224,000-117,635,000-104,156,000-464,217,000-372,204,000-840,096,000-1,106,891,000-864,309,000-1,046,855,000-1,609,441,000-1,064,479,000-1,619,702,000-1,652,980,000-1,833,513,000-2,020,134,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

OBI Pharma, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing cutting-edge therapies for critical medical needs, specifically in the field of cancer, with operations spanning Taiwan and international markets. The company's extensive product pipeline features numerous advanced treatment candidates. These include Adagloxad Simolenin (OBI-822), an active immunity drug for breast cancer designed to stimulate antibody production against the tumor carbohydrate antigen Globo H; OBI-833, an immunity-boosting anti-cancer agent targeting lung cancer; OBI-866 SSEA-4, another active immune-oncology medication; and OBI-888, a passive immunotherapy monoclonal antibody also developed to confront Globo H. Additionally, their portfolio contains OBI-999, an antibody-drug conjugate; OBI-3424, a small-molecule chemotherapy prodrug; OBI-858, a botulinum toxin; and other investigational drugs such as OBI-898 and OBI-998. Founded in 2002, the enterprise is headquartered in Taipei, Taiwan.
URL
https://www.obipharma.com/
IPO date
Dec 12, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT